New Delhi: Drugmaker, Mankind Pharma, has announced the sale of its entire stake in Mahananda Spa and Resorts Private Limited, a Wholly Owned Subsidiary Company to Chalet Hotels Limited for an ...

UTI-Low Duration Fund (IDCW-Q) 33.14 35,00,00,000 0.99 UTI-Low Duration Fund (IDCW-A) 33.14 35,00,00,000 0.99 UTI-Low Duration Fund (Bonus) 33.14 35,00,00,000 0.99 ...

Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the ...

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 98,782.96 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Mankind Pharma Ltd share price previously? Mankind Pharma Ltd share price was down by -1.13% from the previous ...

Short Term Investments 3,004.49 1,216.79 888.40 1,316.49 ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...

OKYO Pharma (OKYO) announces that its lead asset, OK-101, has been officially assigned the United States Adopted Name, USAN, “urcosimod”. Gary Jacob, Ph.D., Chief Executive Officer of Okyo Pha ...

Perform material- and labor-effective extrusion with Thermo Scientific™ Pharma 11 Twin-screw Extruder, which requires only a small amount of active pharmaceutical ingredient, operating at ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

The stakes are clear. Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 billion by streamlining the resource- and time ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...